迈克生物(300463) - 2024 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2024 was ¥616,367,154.02, representing a decrease of 8.88% compared to ¥676,400,369.15 in the same period last year[5] - Net profit attributable to shareholders was ¥120,442,248.90, an increase of 3.05% from ¥116,873,753.42 year-on-year[5] - Basic earnings per share increased by 5.26% to ¥0.20, compared to ¥0.19 in the previous year[5] - Total operating revenue for Q1 2024 was CNY 616,367,154.02, a decrease of 8.9% compared to CNY 676,400,369.15 in the same period last year[21] - Net profit for Q1 2024 increased to CNY 124,243,826.11, compared to CNY 117,826,419.32 in Q1 2023, reflecting a growth of 5.9%[22] - The net profit attributable to the parent company for Q1 2024 was ¥120,442,248.90, an increase from ¥116,873,753.42 in Q1 2023, representing a growth of approximately 2.2%[23] - The total comprehensive income attributable to the parent company was ¥120,078,599.54, compared to ¥108,540,535.42 in the previous year, indicating an increase of about 10.5%[23] - The basic and diluted earnings per share for Q1 2024 were both ¥0.20, up from ¥0.19 in Q1 2023, reflecting a growth of approximately 5.3%[23] Cash Flow - The net cash flow from operating activities significantly dropped by 97.08%, from ¥167,046,659.56 to ¥4,884,287.66[11] - The net cash flow from operating activities was ¥4,884,287.66, a significant decrease from ¥167,046,659.56 in the same period last year[26] - Cash inflow from operating activities totaled ¥765,844,742.92, down from ¥925,552,026.14, marking a decline of about 17.3%[26] - Cash outflow from operating activities was ¥760,960,455.26, slightly up from ¥758,505,366.58, resulting in a marginal increase of approximately 0.2%[26] - The net cash flow from investing activities was -¥39,461,178.86, compared to ¥31,799,722.54 in the previous year, indicating a decline in cash flow from investments[26] - The net cash flow from financing activities was ¥16,166,025.50, down from ¥21,161,398.67, reflecting a decrease of about 23.5%[26] - The total cash and cash equivalents decreased by ¥18,243,411.78 during the quarter, contrasting with an increase of ¥219,019,154.78 in the same period last year[26] - The company received tax refunds amounting to ¥21,428,623.41, a significant increase from ¥1,678,971.78 in the previous year, showing a growth of approximately 1,177.5%[26] Assets and Liabilities - Total assets at the end of the reporting period were ¥8,124,498,732.44, a slight increase of 0.06% from the previous year[5] - The company's total assets as of Q1 2024 amounted to CNY 8,124,498,732.44, slightly up from CNY 8,119,249,307.93 in the previous quarter[19] - Current liabilities decreased to CNY 1,082,471,807.86 from CNY 1,120,605,110.52 in the previous quarter, a reduction of 3.4%[19] - The total liabilities decreased to CNY 1,412,015,783.97 from CNY 1,507,787,287.39, a decline of 6.3%[19] - The company's total equity increased to CNY 6,712,482,948.47 from CNY 6,611,462,020.54, reflecting a growth of 1.5%[19] Shareholder Information - The total number of common shareholders at the end of the reporting period is 38,606[12] - The largest shareholder, Tang Yong, holds 11.11% of shares, totaling 68,062,301 shares, with 17,700,000 shares pledged[12] - The top ten shareholders hold a combined total of 68.67% of the shares[12] Business Operations - The company has initiated the transition from direct sales to distribution, completing the transfer of direct sales business in the Chongqing area[14] - The company plans to deregister its wholly-owned subsidiary, Beijing Dami Microbiology Technology Co., Ltd., which has no operational business as of September 30, 2023[14] - The company has completed the acquisition of 100% equity in Beijing Dami Microbiology Technology Co., Ltd. in phases since November 2020 and March 2022[14] - The company has no significant impact on its overall business development and profitability from the deregistration of Beijing Dami Microbiology[14] Market Outlook - The company emphasizes the positive future outlook for the molecular diagnostics sector and digital PCR technology applications[14] Financial Metrics - Financial expenses decreased by 38.48% to ¥3,828,016.16, attributed to lower interest expenses and increased foreign exchange gains[10] - Investment income fell by 51.15% to ¥1,850,226.43, due to a decline in returns from wealth management products[10] - The company’s weighted average return on equity was 1.87%, slightly up from 1.84% year-on-year[5] - Research and development expenses for Q1 2024 were CNY 59,524,079.57, slightly up from CNY 58,345,527.09 in Q1 2023[22] - The company reported a decrease in financial expenses to CNY 3,828,016.16 from CNY 6,222,293.94 in the previous year, a reduction of 38.5%[22] - The company reported a 54.84% decrease in trading financial assets, primarily due to the redemption of bank wealth management products[9]